APS : Monday, 14 January 2019
ALGIERS- A partnership agreement was signed Monday, in Algiers, between the Algerian-Turkish Abdi Ibrahim Remede Pharma (AIRP) and the German pharmaceutical company Boehringer Ingelheim for the local production
of hypertension and diabetes drugs.
This €20 million agreement will consist in producing the medicines “Micardi.Plus” (against high blood pressure) and “Jardians” (against Type 2 diabetes), said these two partners in the signing ceremony.
The production of these two medicines will be ensured by AIRP’s production plant in the new city of Sidi Abdallah (Zeralda).
According to the director general of Boehringer Ingelheim, Bachir Batel, the production of drugs to treat type 2 diabetes (Jardians) will start in the second quarter of 2019 and will be available in the second half of 2023.
The production of hypertension drugs will start once the technology transfer will be completed by April 2021, he said, underlining that it will be available in Algeria in the second quarter of 2021.
Concerning the price of these two medicines, he said that they will be marketed “at affordable prices.”
For his part, AIRP’s representative Mohamed Lamine Bousteila said investing €20 million in this project comprises equipment, technology transfer and training.
